Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Sodium fluorescein→

Sodium fluorescein Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
518-47-8
PubChem CID
10608
Molecular formula
C20H10Na2O5
Molecular weight
376.3 g/mol

Identification source: PubChem record (CID 10608). The linked PubChem record is provided for identity reference. Confirm the exact salt, hydrate, isomer, mixture, or product form against authoritative source documentation when defining the assessment scope.

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Fluorescent diagnostic dye; ophthalmic and angiographic imaging agent

Mechanism of action

Fluorescein absorbs blue light and emits green-yellow fluorescence. It is used as a tracer to visualise ocular-surface defects or, after intravenous administration, retinal and choroidal vascular circulation; sodium is a counter-ion and does not change the fluorescein chromophore.

General use cases

  • Diagnostic fluorescein angiography of the retina and choroid following intravenous administration
  • Ocular-surface staining to identify corneal epithelial defects and assess tear-film integrity when used in topical ophthalmic preparations
Active moiety: fluorescein (Simple salt/counter-ion form; shares the same API pharmacology and general use cases.)

Fluorescein is the diagnostic dye moiety; sodium is the counter-ion. Use depends on route and product (e.g. intravenous retinal angiography versus topical ocular staining).

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Sodium fluorescein Environmental Risk Assessment (ERA) (the Sodium fluorescein ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.